Abstract：
Drug-induced liver injury (DILI) is a newly discovered adverse drug reaction of Compound Congrong Yizhi Capsules (CCYC) in the treatment of vascular dementia (VD), and targeted pharmaceutical care is urgently needed to be explored.
DILI was found in a patient who was admitted to the hospital with a diagnosis of VD after treatment with Compound Congrong Yizhi Capsules. According to the guidelines, the patient was initially treated with magnesium isoglycyrrhizinate injection. After 4 days, the clinical pharmacist monitored liver function: alanine aminotransferase (ALT): 153 IU/L, aspartate aminotransferase (AST): 160 IU/L, total bilirubin (TBil): 4.5 µmol/L, and alkaline phosphatase (ALP): 551 IU/L, which indicated that DILI was further aggravated. In addition, the increased blood pressure (156/65 mmHg) indicated the requirement to adjust the medication. Then, the hepatoprotective drugs were adjusted with reduced glutathione combined with ursodeoxycholic acid. After 12 days of treatment, the liver function was significantly improved, the clinical treatment was effective, and the blood pressure was controlled stably with no obvious adverse drug reactions.
With pharmaceutical care guided by clinical pharmacists, the DILI caused by Compound Congrong Yizhi capsules could be reversed to improve the clinical outcome and avoid the occurrence of serious complications.
DILI was found in a patient who was admitted to the hospital with a diagnosis of VD after treatment with Compound Congrong Yizhi Capsules. According to the guidelines, the patient was initially treated with magnesium isoglycyrrhizinate injection. After 4 days, the clinical pharmacist monitored liver function: alanine aminotransferase (ALT): 153 IU/L, aspartate aminotransferase (AST): 160 IU/L, total bilirubin (TBil): 4.5 µmol/L, and alkaline phosphatase (ALP): 551 IU/L, which indicated that DILI was further aggravated. In addition, the increased blood pressure (156/65 mmHg) indicated the requirement to adjust the medication. Then, the hepatoprotective drugs were adjusted with reduced glutathione combined with ursodeoxycholic acid. After 12 days of treatment, the liver function was significantly improved, the clinical treatment was effective, and the blood pressure was controlled stably with no obvious adverse drug reactions.
With pharmaceutical care guided by clinical pharmacists, the DILI caused by Compound Congrong Yizhi capsules could be reversed to improve the clinical outcome and avoid the occurrence of serious complications.
摘要：
背景：药物性肝损伤（DILI）是新发现的复方康荣益智胶囊（CCYC）治疗血管性痴呆（VD）的药物不良反应，有针对性的药学服务亟待探索。
方法：在接受复方康荣益智胶囊治疗后诊断为VD的患者中发现了DILI。根据指导方针,患者最初接受异甘草酸镁注射液治疗。4天后,临床药师监测肝功能：丙氨酸转氨酶（ALT）：153IU/L，谷草转氨酶（AST）：160IU/L，总胆红素（TBil）：4.5μmol/L，和碱性磷酸酶（ALP）：551IU/L，这表明DILI进一步恶化。此外,血压升高（156/65mmHg）表明需要调整药物治疗。然后，用还原型谷胱甘肽联合熊去氧胆酸调整保肝药物。治疗12天后，肝功能明显改善,临床治疗有效，血压控制稳定,无明显药物不良反应。
结论：在临床药师的指导下，可逆转复方康荣益智胶囊引起的DILI，改善临床疗效，避免严重并发症的发生。
方法：在接受复方康荣益智胶囊治疗后诊断为VD的患者中发现了DILI。根据指导方针,患者最初接受异甘草酸镁注射液治疗。4天后,临床药师监测肝功能：丙氨酸转氨酶（ALT）：153IU/L，谷草转氨酶（AST）：160IU/L，总胆红素（TBil）：4.5μmol/L，和碱性磷酸酶（ALP）：551IU/L，这表明DILI进一步恶化。此外,血压升高（156/65mmHg）表明需要调整药物治疗。然后，用还原型谷胱甘肽联合熊去氧胆酸调整保肝药物。治疗12天后，肝功能明显改善,临床治疗有效，血压控制稳定,无明显药物不良反应。
结论：在临床药师的指导下，可逆转复方康荣益智胶囊引起的DILI，改善临床疗效，避免严重并发症的发生。
